Therefore, we suggest that CK1ε or the β-catenin/TCF signaling might be potential targets for improvement of tumor regression and outcomes, particularly in patients who harbor high-DDX3/high-nuclear β-catenin or high-DDX3/high-pDvl2/high-nuclear β-catenin tumors. This evidence concerns the gene HNF4A and neoplasm.